[Fatty liver disease--mechanism, clinical significance and factors with a special regard to primary hepatotropic viruses].
Fatty liver disease is one of most frequently diagnosed hepatopathies while detailed examination of potential causes of liver enzymes abnormalities is done. Despite its isolated nosology fatty liver disease often co-exists with other liver pathologies or - more often - it is their natural consequence. Liver steatosis is also more often found in primary hepatotropic viral infections. However, it's more prevalent among HCV (hepatitis C virus) infected persons than in those HBV (hepatitis B virus) infected. It is described in 30-70% routinely pursued liver biopsies in HCV infected individuals. Hitherto, there were many analyses concerning clinical and prognostic implications pursued of HCV influence upon inflammatory and fibrotic process of the liver. This article is an up-to-date review of current clinical and therapeutic implications of hepatosteatosis supported by referent study results.
Smoliński
Patryk
P
Katedry i Kliniki Chorób Zakaźnych, Chorób Watroby i Nabytych Niedoborów Odporności Akademii Medycznej we Wrocławiu. ps88@mp.pl
Simon
Krzysztof
K
Gładysz
Andrzej
A
Nowak
Marcin
M
Dolińska-Krajewska
Barbara
B
D000998:Antiviral Agents / Q000627:therapeutic use; D001706:Biopsy; D015992:Body Mass Index; D005234:Fatty Liver / Q000175:diagnosis / Q000628:therapy* / Q000821:virology*; D005260:Female; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications*; D003699:Hepatitis D / Q000150:complications; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000821:virology; D008297:Male; D028361:Mitochondrial Diseases / Q000150:complications / Q000378:metabolism; D018384:Oxidative Stress; D012307:Risk Factors; D017678:Sex Distribution
D000998:Antiviral Agents; D016898:Interferon-alpha